Researchers used genetic engineering to produce the modified vaccine that “expresses a protein from the surface of the MERS virus, known as a spike protein, on the surface of the rabies virus.” In mouse models, the vaccine protected the mice against both MERS and rabies. The researchers are also planning on testing the vaccine in camels, a reservoir of MERS virus.
The development of the MERS-rabies vaccine could quicken the discovery of a MERS vaccine for human beings.
“This is the first time anyone has used this strategy to create a MERS vaccine,” said Matthew B. Frieman, PhD, an associate professor of microbiology and immunology at the medical school and lead researcher on the study. “This could give us a powerful mechanism to fight the virus.”
More articles on healthcare quality:
Florida hospital first to commit to all 12 Actionable Patient Safety Solutions
Mumps outbreak in Arkansas tops 1,800 cases
‘Nightmare bacteria’ detected on US pig farm
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.